Does PT-141 work for women's low libido (HSDD)?
For one specific group, yes, this is the one use the FDA approved. Bremelanotide, sold as Vyleesi, is approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. In its phase 3 trials it improved measures of sexual desire and reduced the distress associated with low desire compared with placebo. Not everyone responded. Postmenopausal use and compounded PT-141 are off-label.
What is HSDD?
Hypoactive sexual desire disorder (HSDD) is persistently low or absent sexual desire that causes you personal distress, and that is not better explained by a medical or psychiatric condition, relationship problems, or a medication you are taking. The distress is not an optional part of the definition. Low desire that does not bother you is not a disorder.
The approved indication narrows it further, and the two words matter:
- Acquired means desire used to be higher for you and has since dropped. It is not lifelong low desire.
- Generalized means it happens across situations and partners, not only in one specific context.
- Premenopausal is the population the approval covers. This is the part most often glossed over online.
Vyleesi is FDA-approved for acquired, generalized HSDD in premenopausal women only. Use after menopause is off-label. Compounded PT-141 is not FDA-approved in any population. A licensed provider decides what is appropriate for you.
What the research actually showed
Approval rested on two large phase 3 trials in premenopausal women with acquired, generalized HSDD. Compared with placebo, bremelanotide improved scores for sexual desire and reduced the distress associated with low desire. Those are the endpoints the FDA reviewed, in that population, at the approved dose and by injection.
The honest framing matters as much as the result. This is not a switch. A meaningful share of participants did not respond, the changes measured were on desire and distress scales rather than on the number of satisfying events alone, and nausea was common enough to be the main reason people stopped. If you want the trial detail and the numbers, they live on the science of PT-141 rather than here.
Vyleesi vs compounded PT-141
Both are bremelanotide. What differs is the regulatory status, the device, and the price.
| Vyleesi (brand) | Compounded PT-141 | |
|---|---|---|
| Regulatory status | FDA-approved for acquired, generalized HSDD in premenopausal women | Not FDA-approved. Prepared by a licensed pharmacy on a prescription |
| Who makes it | The brand manufacturer, one standardised product | A licensed US compounding pharmacy |
| Format | Single-use prefilled autoinjector | Typically a vial for subcutaneous injection, dosed by your prescriber |
| Approved dosing | 1.75 mg, at least 45 minutes before anticipated activity, max one dose per 24 hours and 8 per month | Set by your prescriber, using the approved product as the reference point |
| Cost | Commonly several hundred dollars for a small pack | At Expert Health, $166/mo or $497 for about a 10-week supply |
| Insurance | Sometimes covered with prior authorization, often excluded | Generally paid out of pocket |
Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Compounded PT-141 is not a generic of Vyleesi and should not be treated as equivalent to it.
Why compounded exists at all: a licensed prescriber can have a medication prepared for a patient by a compounding pharmacy, which is a long-standing part of US pharmacy practice regulated by the FDA and state boards. That is a different thing from a gray-market vendor shipping vials with no prescription. See where to get PT-141 online.
What about after menopause?
The FDA approval covers premenopausal women. It does not extend to postmenopausal women, because that is not the population the pivotal trials enrolled. Prescribing it after menopause is off-label, which means it is legal for a provider to do based on clinical judgement, but it is outside the evidence the approval was based on and you should be told that plainly before you start.
If low desire started around perimenopause or after, it is worth separating the causes before reaching for anything. Vaginal dryness and pain with sex, sleep disruption, mood, thyroid, and medications including some antidepressants and hormonal contraceptives all affect desire, and several of them have better-established treatments than an off-label peptide. A good consult starts there.
What a consult covers
Expert Health prices compounded PT-141 at $166 per month, or $497 for about a 10-week supply. Before anything is prescribed, a US-licensed provider works through:
- Whether what you are describing fits acquired, generalized HSDD, or whether something else is driving it
- Your menopausal status, and whether use would be on-label or off-label for you
- Blood pressure and cardiovascular history, which is a hard limit rather than a preference
- Your medications, including hormonal contraception, hormone therapy, antidepressants, and oral naltrexone
- How it is dosed and timed, and what to expect from nausea, which is the most common side effect
The consult is free and there is no obligation to buy. Compounded PT-141 is not FDA-approved, and a provider has to agree treatment is appropriate before anything ships.
Frequently asked questions
Does PT-141 work for women's low libido?
What is HSDD?
Is PT-141 only for premenopausal women?
What is the difference between Vyleesi and compounded PT-141?
Does PT-141 increase arousal and orgasm, or only desire?
Can women take PT-141 with hormone therapy or birth control?
Is PT-141 safe to use at any point in the menstrual cycle?
How is PT-141 different from Addyi?
Sources
- Vyleesi (bremelanotide injection) Prescribing Information · U.S. FDA Label
- Vyleesi (bremelanotide) label and indication · DailyMed / National Library of Medicine
- Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration
This article is for general educational purposes and is not medical or legal advice. Statements have not been evaluated by the FDA, and treatments referenced are not intended to diagnose, treat, cure, or prevent any disease. Compounded medications are not FDA-approved. Individual results vary. Always consult a licensed provider before starting any treatment.
Explore libido treatments
Start with PT-141.
As low as $166/mo. Prescribed by a US-licensed provider, compounded by a licensed US pharmacy, and shipped free to your door.
See PT-141 and pricingNot sure it is the right fit? Speak with a health specialist, free, or browse all treatments.